Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)

BACKGROUND: Chemotherapy with biologics followed by liver surgery improves the resection rate and survival of patients with colorectal liver metastasis (CRLM). However, no prospective study has compared the outcomes of chemotherapy with bevacizumab (BEV) versus cetuximab (CET). METHODS: The ATOM stu...

Full description

Saved in:
Bibliographic Details
Published in:Br J Cancer
Main Authors: Oki, Eiji, Emi, Yasunori, Yamanaka, Takeharu, Uetake, Hiroyuki, Muro, Kei, Takahashi, Takao, Nagasaka, Takeshi, Hatano, Etsuro, Ojima, Hitoshi, Manaka, Dai, Kusumoto, Tetsuya, Katayose, Yu, Fujiwara, Toshiyoshi, Yoshida, Kazuhiro, Unno, Michiaki, Hyodo, Ichinosuke, Tomita, Naohiro, Sugihara, Kenichi, Maehara, Yoshihiko
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738101/
https://ncbi.nlm.nih.gov/pubmed/31285591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0518-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items